Is this target worth building a program around?
A target assessment bringing together human biology, mechanism, druggability, safety and the competitive picture.
CapabilitiesScience, development
Science, development
and strategy.
Engage Quinn for research, analysis and design across discovery, development and commercialization—from targets and trials to investment, launch and medical strategy.
Discuss a projectResearch & discovery
From a biological question to the targets, molecules and experiments worth pursuing.
What should we design and test next?
Computational molecule, binder and protein designs assessed against your criteria, with the experiments needed to evaluate them.
What does our data reveal?
Analysis of omics, screening or other research data, with interpretable findings and reproducible code.
Translational science
Connect the biology to the patients, biomarkers and doses a development program needs.
Does the preclinical evidence support advancing?
An assessment of human relevance, the assumptions that matter and the evidence needed for the next stage.
Which biomarker, patient group or dose should we carry forward?
Biomarker and population analysis, exposure–response modeling and a plan to resolve the remaining uncertainty.
Clinical development
Work through the choices that determine what a study can establish and where a program can go.
What trial would answer the development question?
Population, endpoint, comparator and dose recommendations, with statistical design and simulations where the evidence supports them.
What is the strongest development path?
An assessment of clinical evidence, regulatory precedent, competitive context and the studies needed for approval and access.
Safety & toxicology
Understand the signal, its likely explanation and what it means for the program.
What is driving this safety concern?
An integrated assessment of mechanism, exposure, class evidence and alternative explanations, with the work needed to distinguish them.
How should we respond to an emerging signal?
A benefit–risk assessment, targeted analyses and recommendations for risk management or further evidence.
Portfolio & commercial strategy
Bring the science, development outlook and business case into the same decision.
Where should we invest, and what should we stop funding?
Portfolio prioritization, valuation scenarios and resource allocation, with the assumptions that could change the recommendation.
Should we license, acquire, build or partner?
Scientific and commercial due diligence, a view of the alternatives and the next questions to resolve.
Where should this product compete?
Indication and launch sequencing, pricing and market access assessments, competitive scenarios and lifecycle strategy.
CMC & regulatory
Resolve the manufacturing, supply and regulatory choices that shape the path to patients.
What could delay our next milestone?
An assessment of process, formulation, analytical and regulatory gaps, with priorities for the work that matters most.
How should we make and supply this product?
Manufacturing economics, build-or-outsource options, supply risks and the regulatory implications of each.
What does the submission need to establish?
Regulatory strategy and precedent, evidence-gap assessment and drafted scientific sections based on your data.
Medical affairs & access
Make the evidence useful to clinicians, payers and the teams shaping a product’s future.
What can we credibly say about this product?
A scientific narrative and comparative evidence assessment, with support for each claim and the limits made clear.
What evidence would change practice or access?
Evidence-generation and real-world analysis plans, health-economic work and a clear account of the gaps to address.
What should our medical strategy focus on?
Medical launch, publication and field-engagement priorities grounded in the evidence and the needs of the field.
Quinn carries out research, computational analysis, design and strategic work. Your team or its partners carry out physical experiments, clinical operations and manufacturing. Proposed candidates and study designs are evaluated through the relevant scientific and operational review.
What is your team working on?
A few sentences are enough to start.